CDKN2A/B同型缺失是2021年世界卫生组织认定的IDH突变星形神经胶质瘤的关键分子标记。我们旨在研究定性和定量MRI参数是否能够预测IDH突变星形神经胶质瘤中CDKN2A/B同型缺失的状态。该研究纳入了来自两个机构的88名患有IDH突变星形神经胶质瘤的患者（平均年龄±标准差为42.0±11.9岁；40名女性和48名男性）的术前MRI数据（其中76人没有CDKN2A/B同型缺失，12人有）。进行了定性成像评估。通过自动肿瘤分割评估平均表观弥散系数（ADC）、ADC的第5百分位数、平均归一化脑血容积（nCBV）和nCBV的第95百分位数。对所有88名患者和47名组织学分级为3和4的亚组进行逻辑回归分析以确定与CDKN2A/B同型缺失相关的因素。使用接受者操作特征曲线（ROC曲线）下面积（AUC）评估逻辑回归模型的判别效能。 在所有患者的多变量分析中，浸润模式（OR=4.25，p=0.034）、最大直径（OR=1.07，p=0.013）和nCBV的第95百分位数（OR=1.34，p=0.049）是CDKN2A/B同型缺失的独立预测因子。相应模型的AUC、准确性、敏感度和特异度分别为0.83（95%置信区间[CI]，0.72-0.91）、90.4%、83.3%和75.0%。在组织学分级为3和4的亚组的多变量分析中，浸润模式（OR=10.39，p=0.012）和nCBV的第95百分位数（OR=1.24，p=0.047）是CDKN2A/B同型缺失的独立预测因子。相应模型的AUC准确度、敏感度和特异度为0.76（95% CI，0.60-0.88）、87.8%、80.0%和58.1%。 浸润模式的存在、更大的最大直径和更高的nCBV的第95百分位数可能是IDH突变星形神经胶质瘤中CDKN2A/B同型缺失的有用MRI生物标志物。 版权所有2023年韩国放射学会。

Cyclin-dependent kinase inhibitor (CDKN)2A/B homozygous deletion is a key molecular marker of isocitrate dehydrogenase (IDH)-mutant astrocytomas in the 2021 World Health Organization. We aimed to investigate whether qualitative and quantitative MRI parameters can predict CDKN2A/B homozygous deletion status in IDH-mutant astrocytomas.Preoperative MRI data of 88 patients (mean age ± standard deviation, 42.0 ± 11.9 years; 40 females and 48 males) with IDH-mutant astrocytomas (76 without and 12 with CDKN2A/B homozygous deletion) from two institutions were included. A qualitative imaging assessment was performed. Mean apparent diffusion coefficient (ADC), 5th percentile of ADC, mean normalized cerebral blood volume (nCBV), and 95th percentile of nCBV were assessed via automatic tumor segmentation. Logistic regression was performed to determine the factors associated with CDKN2A/B homozygous deletion in all 88 patients and a subgroup of 47 patients with histological grades 3 and 4. The discrimination performance of the logistic regression models was evaluated using the area under the receiver operating characteristic curve (AUC).In multivariable analysis of all patients, infiltrative pattern (odds ratio [OR] = 4.25, p = 0.034), maximal diameter (OR = 1.07, p = 0.013), and 95th percentile of nCBV (OR = 1.34, p = 0.049) were independent predictors of CDKN2A/B homozygous deletion. The AUC, accuracy, sensitivity, and specificity of the corresponding model were 0.83 (95% confidence interval [CI], 0.72-0.91), 90.4%, 83.3%, and 75.0%, respectively. On multivariable analysis of the subgroup with histological grades 3 and 4, infiltrative pattern (OR = 10.39, p = 0.012) and 95th percentile of nCBV (OR = 1.24, p = 0.047) were independent predictors of CDKN2A/B homozygous deletion, with an AUC accuracy, sensitivity, and specificity of the corresponding model of 0.76 (95% CI, 0.60-0.88), 87.8%, 80.0%, and 58.1%, respectively.The presence of an infiltrative pattern, larger maximal diameter, and higher 95th percentile of the nCBV may be useful MRI biomarkers for CDKN2A/B homozygous deletion in IDH-mutant astrocytomas.Copyright © 2023 The Korean Society of Radiology.